Search

everythinglearnresearchcommunity

for

Search:↓

A user noticed increased hair loss and was prescribed Betamethasone dipropionate 0.05% lotion by a dermatologist. Another user suggested changing doctors and asking for finasteride instead.

Finasteride helped users feel better about hair loss, with some experiencing positive changes in confidence and reduced anxiety. Despite initial concerns, users reported satisfaction with the treatment over several months.

Visible hair improvement after 10 weeks using minoxidil, estradiol enanthate, acetophenide algestone, and bicalutamide. The user is a 25-year-old male with reduced testosterone levels, expressing a preference for less masculinity.

Dr. Tsuji and Riken announced a hair cloning cure with a 98.9% success rate, expected to be released in 10 years. Users expressed hope and skepticism about the affordability and timeline of the treatment.

The conversation is about a user experiencing positive hair regrowth results using 1mg of dutasteride, 10% minoxidil, and occasional microneedling, after unsatisfactory results with finasteride. Other users express interest in switching to dutasteride and share similar sentiments about finasteride.

The conversation is about hair loss treatments, specifically discussing RU58841, with concerns about its safety and lack of research. Alternatives like finasteride, dutasteride, and minoxidil are mentioned, with some users sharing personal experiences and side effects.

The user experienced significant hair and beard regrowth using 0.5mg dutasteride and 5mg oral minoxidil over a year, despite initial shedding. They reported no major side effects, except for increased body hair growth.

Low oxytocin levels in hair are linked to reduced empathy and may affect hair growth. Cinnamic acid can promote hair growth by activating oxytocin receptors.

The user has been using finasteride and minoxidil for hair loss but experienced worsening temple recession. They suspect they might be more sensitive to testosterone and are considering trying RU58841 or CB 03 01 as additional treatments.

The conversation is about the FDA approval of WINLEVI for acne treatment and the anticipation of Breezula, a hair loss treatment using the same active ingredient, which may indicate a positive future for Breezula's release. There is disappointment that Breezula's results are not optimal, but it is seen as progress in hair loss treatment.

A user needs to stop finasteride for 7 days to donate blood due to haemochromatosis. They are concerned if this break will affect their hair loss progress after 6 weeks of use.

The user experienced balance issues after taking finasteride for 2 months and is seeking advice on whether to continue. They are concerned about potential additional side effects.

A phase 3 trial for Breezula (clascoterone solution) to treat male pattern hair loss has been listed, with 726 participants and a completion date of January 2025. Other treatments mentioned include Aneira Pharma's combination of minoxidil and latanoprost, Triple Hair's combination of minoxidil, latanoprost, and finasteride, and a new microneedling and LLLT device called StimuSIL.

The conversation is about hair loss treatments, specifically Minoxidil, Finasteride, and RU58841. Users discuss personal experiences and preferences for starting these treatments.

The conversation humorously discusses a visit to the Everychem laboratory, with a focus on hair loss treatments like Minoxidil, finasteride, and RU58841. The tone is satirical.

The conversation discusses choosing between titanium fixed needles and a pen with disposable needles for hair loss treatment at a 1.5mm depth. The preference is for disposable needles for better sanitization.

The conversation discusses HMI 115, a new hair loss treatment with promising results, showing a significant increase in hair density after two months. Some users are skeptical, while others are hopeful for its release and potential affordability.

FOL-005 claims to be more effective than Minoxidil and Finasteride but lacks anti-DHT properties, leading to potential reduced efficacy over time. Concerns are raised about misleading marketing and the safety of alternative treatments like Pyrilutamide and Clascoterone.

High cost of studying 3α-Hydroxysteroid dehydrogenase in hair loss led to suggestions of crowdfunding for research. Users discussed using Procyanidin B2/melatonin topical treatment and tracking funds with blockchain.

The user has been using finasteride for hair loss and is considering adding RU58841. They ask about RU58841's effectiveness, potential heart side effects, duration of action, dosage increase over time, transitioning to GT20029, and where to find the liquid form.

A boyfriend's hair improved significantly over 10 months using minoxidil, steroid cream, antihistamine cream, and wild growth oil, with a strict cleaning regimen. His partner's dedicated care contributed to the transformation.

RU58841 may cause heart-related side effects like palpitations and chest pain, though evidence is mostly anecdotal. Users report mixed experiences, with some stopping due to side effects and others using it without issues, but concerns about its safety and sourcing remain.

The conversation discusses the effectiveness of switching from finasteride to dutasteride for hair loss treatment, with some users suggesting adding oral minoxidil for further improvement. The original poster is considering a hair transplant and is concerned about perceived thinning, despite others noting improvement or stability with dutasteride.

Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgen receptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.

The conversation discusses mixing finasteride (Essengen-F) with a multi-peptide serum for hair density. The main concern is whether these products can be used together safely.

The conversation discusses the ineffectiveness of tablet forms of dutasteride for hair loss due to poor absorption compared to soft gel capsules. It suggests switching to FDA-approved soft gel capsules for better results, as tablets may not adequately suppress DHT levels.

A 27-year-old male with ADHD is experiencing hair thinning and is starting a treatment with topical finasteride (0.025%) and minoxidil (5%). He is addressing high prolactin levels and low vitamin D, while managing side effects from ADHD medication.

The conversation is about baricitinib, a medicine that can help with hair loss, and why it isn't more popular or widely discussed. No specific experiences with the treatment were shared.

First patient dosed with Pyrilutamide (Kintor) Phase III for hair loss treatment. Pyrilutamide differs from approved treatments as it competes with DHT to bind hair follicles, potentially reducing side effects.

Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.